UAE drug regulator granted marketing authorization for ANKTIVA in BCG-unresponsive non-muscle invasive bladder cancer, covering CIS and papillary-only disease.
The clearance also covers metastatic non-small cell lung cancer in combination with immune checkpoint inhibitors for patients progressing on standard therapy.
The approvals were first registered on July 24, 2026, expanding ANKTIVA’s authorized footprint to 34 countries.
IBRX•
